drugset / Trial / NCT03001882

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT03001882 ↗

Phase 2 Completed 230 enrolled Bristol-Myers Squibb Yale University · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).

Timeline

Start
2017-03-29
Primary completion
2022-02-17
Completion
2023-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody — —
Subject Nivolumab Monoclonal antibody — —